Business Standard

Saturday, January 11, 2025 | 05:33 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Covid-19 vaccine: Bharat Biotech completes recruitment for phase 3 trials

More than 5,000 people have been given both shots of the vaccine; efficacy data around March

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Premium

Covaxin is yet to generate any efficacy data and has not submitted any interim analysis data to the SEC.

Sohini Das Mumbai
Amidst a heated debate surrounding the approval of Covaxin, Bharat Biotech's Covid-19 vaccine candidate, the Hyderabad based firm on Thursday said that it has completed recruitment of 25,800 people for its phase 3 efficacy trial.

The last leg of enrolment for the trials happened in the last week of December, with the company saying it was half-way through for its recruitment target. On January 2 the company had informed that it has recruited 23,000 volunteers.  The efficacy data is expected around March and over 5000 people have already received both the shots of the vaccine.

The subject expert committee (SEC)

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in